This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Adjuvant combination for increased influenza vaccine efficacy	<p>Combining the adjuvants alum and monophosphoryl lipid A (MPL) could help improve influenza vaccine efficacy. In mice, an influenza vaccine formulated with both adjuvants generated protective CD8⁺ memory T cell responses and increased protection against influenza A challenge compared with vaccines that contained either adjuvant alone. Next steps include studying whether the adjuvant combination protects against different strains of influenza.</p> <p>GlaxoSmithKline plc's adjuvant AS04, a combination of alum and MPL, is used in Cervarix, a vaccine approved to prevent HPV types 16 and 18.</p> <p>SciBX 4(19); doi:10.1038/scibx.2011.555 Published online May 12, 2011</p>	<p>Patent pending; available for licensing through the National Jewish Health Technology Transfer Office</p> <p>Contact: Emmanuel Hilaire, National Jewish Health, Denver, Colo. e-mail: HilaireE@NJHealth.org</p>	<p>MacLeod, M.K.L. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online April 25, 2011; doi:10.1073/pnas.1104588108</p> <p>Contact: Philippa Marrack, National Jewish Health, Denver, Colo. e-mail: marrackp@njhealth.org</p> <p>Contact: Megan K.L. MacLeod, same affiliation as above e-mail: macleodm@njhealth.org</p>